BJDX (Bluejay) Market Value to Book Value Ratio

Bluejay Diagnostics, Inc. (BJDX) - corporate logo

Bluejay Diagnostics (BJDX) is expanding its clinical presence through partnerships focused on rapid diagnostics for cardiac health and sepsis. The market cap-to-book value ratio illustrates current market sentiment, where the value 0.12 serves as the current metric. While microfluidics patents and FDA requirements create a high barrier to entry, critical liquidity levels and regulatory dependence increase financial risks.

BJDX - Bluejay Diagnostics Corp Market-to-Book Ratio over the range 07/04/2022 - 10/27/2026
Flagship merchandise of Bluejay

Bluejay Diagnostics (BJDX) is aggressively competing for market share in rapid diagnostics against major laboratory networks. Analyzing the price-to-book ratio chart, an investor can see the proportion between the share price and the value of net assets. This multiple measures the market premium over the company's actual capital. This price action reflects market confidence in the company's technological potential. High values confirm optimism but increase the risk of a sharp valuation correction.

Direct competitors

Market Cap to Net Assets Ratio Agilent Technologies|DGX (questdiagnostics.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio ILMN|Market Cap to Net Assets Ratio Exact Sciences Corp|PerkinElmer - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Bio-Rad Corp (BIO)|NNNN - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio soterahealth.com SHC|QuidelOrtho Corporation - Market Capitalization to Book Value Ratio|OPK: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio CareDx|Maravai (MRVI) - Capitalization to Book Value Ratio|FLGT (Fulgent Genetics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio LAB|Market Value to Book Value Ratio Cytek Biosciences (CTKB)|Market Value to Book Value Ratio OraSure Technologies, Inc. OSUR|XGN: Market Cap to Net Assets Ratio|MDxHealth, Inc. - Market-to-Book Ratio|Market Value to Book Value Ratio LUCD (Lucid Diagnostics Inc.)|PRE - Market Capitalization to Book Value|imdxinc.com - Market Capitalization to Book Value Ratio|TRIB (Trinity Biotech) - Market Capitalization to Book Value|PRPH: Market Value to Book Value Ratio|Market Capitalization to Book Value Ainos Corporation|Market Capitalization to Book Value Ratio Co-Diagnostics, Inc. (CODX)|Market Value to Book Value Ratio HSCS (heartsciences.com)|Market Value to Book Value Ratio Biomerica BMRA|CDIO - Market Value to Book Value Ratio|Virax Biolabs Group Ltd - Market Cap to Net Assets Ratio|AWH - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio AXDX|CNTG (CENTOGENE) - Market-to-Book Ratio|Enzo Biochem Inc. (ENZ) - Market Value to Book Value Ratio|Market Cap to Book Value Multiple Fresh2|Market Capitalization to Book Value Ratio GENE|Market Capitalization to Book Value Ratio 23andMe Inc ME|PMD: Market Cap to Net Assets Ratio